![Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial](https://www.mdpi.com/cancers/cancers-13-04856/article_deploy/html/images/cancers-13-04856-g001.png)
Cancers | Free Full-Text | Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
![Biomedicines | Free Full-Text | Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study Biomedicines | Free Full-Text | Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study](https://pub.mdpi-res.com/biomedicines/biomedicines-10-01657/article_deploy/html/images/biomedicines-10-01657-g001.png?1657433511)
Biomedicines | Free Full-Text | Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
![IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases](https://www.mdpi.com/ijms/ijms-24-09531/article_deploy/html/images/ijms-24-09531-g001-550.jpg)
IJMS | Free Full-Text | Free Light Chains κ and λ as New Biomarkers of Selected Diseases
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma | Haematologica
![Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/2-Table1-1.png)
Table 1 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Table 2 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/ lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41408-022-00732-3/MediaObjects/41408_2022_732_Fig1_HTML.png)
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal
![Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41408-022-00732-3/MediaObjects/41408_2022_732_Fig3_HTML.png)
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal
![JCM | Free Full-Text | The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis JCM | Free Full-Text | The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis](https://www.mdpi.com/jcm/jcm-10-01274/article_deploy/html/images/jcm-10-01274-g001-550.jpg)
JCM | Free Full-Text | The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels | Haematologica
![Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory](https://wardelab.com/wp-content/uploads/2020/06/18_2_4.jpg)
Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory
Prole plot of kappa/lambda FLC ratio over time by patientDashed line,... | Download Scientific Diagram
![Comparison of kappa FLC, lambda FLC, and kappa/lambda FLC ratios in... | Download Scientific Diagram Comparison of kappa FLC, lambda FLC, and kappa/lambda FLC ratios in... | Download Scientific Diagram](https://www.researchgate.net/publication/5930043/figure/fig1/AS:216390800809984@1428602995144/Comparison-of-kappa-FLC-lambda-FLC-and-kappa-lambda-FLC-ratios-in-patients-with-and.png)
Comparison of kappa FLC, lambda FLC, and kappa/lambda FLC ratios in... | Download Scientific Diagram
![In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study | Blood Cancer Journal In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-022-00751-0/MediaObjects/41408_2022_751_Fig1_HTML.png)
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study | Blood Cancer Journal
![Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust Demystifying Serum Free Light Chains – a guide for primary care - Manchester University NHS Foundation Trust](https://mft.nhs.uk/app/uploads/2023/01/Myeloma-diagnostic-tool.png)